McKinsey under fire for consulting on opioid sales  

Global consulting firm McKinsey & Co. is facing criticism for its role in opioid marketing for Johnson & Johnson and Purdue Pharmaceuticals, The New York Times reports.

The consulting firm's work has been cited in cases against pharmaceutical companies in Oklahoma, Massachusetts and New Jersey. The Oklahoma case cites its work for Johnson & Johnson on how to better influence prescription behavior. In Massachusetts, the company is named for helping Purdue Pharma "turbocharge" OxyContin sales, according to the report.

McKinsey is not a defendant in the lawsuits.  

In a statement to The New York Times, McKinsey said: "Our historical work for clients in this industry was designed to support the legal prescription and use of our clients' products. Opioids have had a devastating impact on our communities, however, and we are no longer advising clients on any opioid-specific business on a global basis."

Johnson & Johnson said it still uses McKinsey for projects not related to opioids. 

Read the full story here


More articles on opioids:

US opioid-prescribing rates can be nearly 30% higher than in other countries
NIH to award $155M in grants to improve opioid abuse treatment
How 76B opioid pills were distributed in US: A state-by-state breakdown

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months